• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Derrick Sung Joins Aerin Medical as Chief Financial Officer

    11/20/23 9:00:00 AM ET
    $IRTC
    $LUNG
    Medical/Dental Instruments
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $IRTC alert in real time by email

    A seasoned leader, Sung brings deep finance, capital markets, and strategy experience across the medical device industry

    Aerin Medical Inc., a company dedicated to providing Ear, Nose and Throat (ENT) physicians with non-invasive solutions for the treatment of chronic nasal conditions, announced today that Derrick Sung has been appointed chief financial officer of the company. Sung brings over 25 years of finance, capital markets, and strategy experience across diverse roles within the medical device industry.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231120576987/en/

    Derrick Sung has been appointed chief financial officer of Aerin Medical. Sung brings over 25 years of finance, capital markets, and strategy experience across diverse roles within the medical device industry. Prior to joining Aerin Medical, Sung was CFO at Pulmonx Corporation where he scaled the finance organization and led the company through significant growth and a successful IPO. (Photo: Business Wire)

    Derrick Sung has been appointed chief financial officer of Aerin Medical. Sung brings over 25 years of finance, capital markets, and strategy experience across diverse roles within the medical device industry. Prior to joining Aerin Medical, Sung was CFO at Pulmonx Corporation where he scaled the finance organization and led the company through significant growth and a successful IPO. (Photo: Business Wire)

    "It is with great pleasure that we welcome Derrick as the latest addition to our leadership team," said Matt Brokaw, CEO of Aerin Medical. "With a proven track record of financial leadership and a wealth of operating expertise, Derrick will play a pivotal role in accelerating our pursuit of a new standard of care for millions of untreated sufferers of ENT conditions."

    Prior to joining Aerin Medical, Sung was CFO at Pulmonx Corporation (NASDAQ:LUNG) where he scaled the finance organization and led the company through significant growth and a successful IPO. Before that, he led strategy and corporate development at iRhythm Technologies (NASDAQ:IRTC). Previously, Sung spent seven years on Wall Street as a senior equity research analyst covering the medical devices sector, directed marketing and business development for Boston Scientific's Neuromodulation division, led management consulting engagements at the Boston Consulting Group, and designed heart catheters as an R&D engineer for Guidant Corporation. He received his Ph.D. in bioengineering from the University of California, San Diego, his Master of Business Administration from San Diego State University, and his Bachelor of Science degree in mechanical engineering from Stanford University.

    "I am excited to join the exceptional team at Aerin Medical as we embark on the next phase of growth," said Sung. "Fueled by compelling fundamentals and a rare financial profile, we are poised to achieve remarkable success."

    About Aerin Medical

    Aerin Medical is a privately held, venture-backed company, with U.S. offices in California and Texas. Aerin's mission is to expand access to meaningful relief for millions of patients suffering from chronic ENT conditions. The company's products, VivAer® for nasal airway obstruction and RhinAer® for chronic rhinitis, leverage Aerin's proprietary temperature-controlled technology, which allows ENT physicians to reliably improve patients' symptoms with unique technologies that are appealing alternatives to invasive surgery. More than 100,000 patients have been treated with Aerin Medical products to date. For more information, please visit www.aerinmedical.com and follow Aerin Medical on Facebook, X, Instagram, LinkedIn and YouTube.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20231120576987/en/

    Get the next $IRTC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IRTC
    $LUNG

    CompanyDatePrice TargetRatingAnalyst
    iRhythm Technologies Inc.
    $IRTC
    9/23/2025$185.00In-line
    Evercore ISI
    iRhythm Technologies Inc.
    $IRTC
    8/20/2025$200.00Buy
    BofA Securities
    Pulmonx Corporation
    $LUNG
    7/31/2025$2.50Overweight → Neutral
    Piper Sandler
    iRhythm Technologies Inc.
    $IRTC
    5/2/2025$130.00Equal Weight → Overweight
    Wells Fargo
    Pulmonx Corporation
    $LUNG
    3/10/2025$17.00Buy
    D. Boral Capital
    Pulmonx Corporation
    $LUNG
    12/11/2024$17.00 → $7.50Buy → Neutral
    Citigroup
    iRhythm Technologies Inc.
    $IRTC
    12/3/2024$86.00Equal Weight
    Wells Fargo
    iRhythm Technologies Inc.
    $IRTC
    10/4/2024$78.00Neutral
    Goldman
    More analyst ratings

    $IRTC
    $LUNG
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Pulmonx Corporation

    SCHEDULE 13G/A - Pulmonx Corp (0001127537) (Subject)

    11/13/25 8:31:01 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by iRhythm Technologies Inc.

    SCHEDULE 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)

    11/13/25 2:34:17 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    iRhythm Technologies Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - iRhythm Technologies, Inc. (0001388658) (Filer)

    11/12/25 5:17:38 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    $IRTC
    $LUNG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    New Data at the Asia Pacific Heart Rhythm Society (APHRS) 2025 Highlight the Performance of iRhythm's Zio Long-Term Continuous Monitoring in an Asian Population

    iRhythm Technologies presented new data during the joint Asia Pacific Heart Rhythm Society (APHRS) and Japan Heart Rhythm Society (JHRS) scientific sessions.Large-scale analysis of more than 400,000 patients1 supports the consistency and generalizability of Zio long-term ECG monitoring (LTCM) performance across populations; median wear and analyzable time among patients identified as Asian (3.4% of the cohort) were comparable to those of non-Asian patients, and findings were consistent with Zio LTCM performance previously reported in the published CAMELOT2 and AVALON3 studies. SAN FRANCISCO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) today announced new dat

    11/21/25 8:10:00 AM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    Pulmonx Reports Third Quarter 2025 Financial Results

    REDWOOD CITY, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the third quarter of 2025 ended September 30, 2025. Recent Highlights Achieved worldwide revenue of $21.5 million in the third quarter of 2025, a 5% increase over the same period last year and an increase of 4% on a constant currency basisDelivered $7.5 million in international revenue in the third quarter of 2025, representing 15% year-over-year growth and an increase of 9% on a constant currency basisDelivered $14.0 million in U.S. revenue in the third quarter of 20

    11/12/25 4:05:00 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    iRhythm Technologies Announces Publication of Large-Scale Study in Heart Rhythm and New Data Presented at AHA Scientific Sessions 2025

    Real-world data across more than 1 million patients published in Heart Rhythm show that 24–48-hour monitoring can miss actionable arrhythmias and highlights the value of iRhythm's Zio® long-term continuous monitoring (LTCM)– even in patients with frequent (i.e., daily) symptoms1Data from more than 742,000 patients presented at the American Heart Association (AHA) Scientific Sessions 2025 confirm that at-home self-application and activation of Zio 14-day patch-based LTCM devices achieve high compliance, strong engagement, and data quality comparable to in-clinic application2Additional large-scale real-world analyses also presented at AHA 2025 provide expanded insights into CKM/CKD risk and re

    11/11/25 8:05:00 AM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    $IRTC
    $LUNG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Talwalkar Abhijit Y exercised 5,312 shares at a strike of $10.71 and sold $924,962 worth of shares (5,312 units at $174.13) (SEC Form 4)

    4 - iRhythm Technologies, Inc. (0001388658) (Issuer)

    11/12/25 4:33:59 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    New insider Sung Derrick claimed ownership of 135,319 shares (SEC Form 3)

    3 - Pulmonx Corp (0001127537) (Issuer)

    11/10/25 5:42:26 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    President and CEO Blackford Quentin S. sold $2,571,907 worth of shares (14,059 units at $182.94), decreasing direct ownership by 8% to 164,979 units (SEC Form 4)

    4 - iRhythm Technologies, Inc. (0001388658) (Issuer)

    11/4/25 5:04:10 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    $IRTC
    $LUNG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Florin Daniel P bought $71,362 worth of shares (23,321 units at $3.06), increasing direct ownership by 25% to 117,231 units (SEC Form 4)

    4 - Pulmonx Corp (0001127537) (Issuer)

    6/5/25 8:39:08 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    Director Talwalkar Abhijit Y bought $500,866 worth of shares (6,664 units at $75.16), increasing direct ownership by 54% to 18,941 units (SEC Form 4)

    4 - iRhythm Technologies, Inc. (0001388658) (Issuer)

    11/5/24 11:59:44 AM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    PRESIDENT AND CEO Williamson Steven S. bought $97,436 worth of shares (14,245 units at $6.84), increasing direct ownership by 7% to 219,531 units (SEC Form 4)

    4 - Pulmonx Corp (0001127537) (Issuer)

    8/22/24 6:41:17 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    $IRTC
    $LUNG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Evercore ISI initiated coverage on iRhythm with a new price target

    Evercore ISI initiated coverage of iRhythm with a rating of In-line and set a new price target of $185.00

    9/23/25 8:17:27 AM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    BofA Securities initiated coverage on iRhythm with a new price target

    BofA Securities initiated coverage of iRhythm with a rating of Buy and set a new price target of $200.00

    8/20/25 8:56:18 AM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    Pulmonx downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Pulmonx from Overweight to Neutral and set a new price target of $2.50

    7/31/25 7:16:23 AM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    $IRTC
    $LUNG
    Leadership Updates

    Live Leadership Updates

    View All

    Pulmonx Announces Appointment of Mehul Joshi as Chief Financial Officer

    REDWOOD CITY, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced the appointment of Mehul Joshi as Chief Financial Officer, effective April 3, 2024. He succeeds John McKune, who has served as the Company's Interim Chief Financial Officer since October 10, 2023, and will transition to his prior role as Vice President, Corporate Controller. "Mehul is an exceptionally accomplished financial executive and I am excited to welcome him to our leadership team. His proven track record of leading global finance teams within large, diversified companies makes him

    4/2/24 4:05:00 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    iRhythm collaborates with Epic to streamline access to Zio® service and drive more seamless connectivity between clinicians and patients

    iRhythm is the first medical device company to join the Epic community, using Aura to drive efficiencies through EHR integrationThe collaboration will expand access to Zio service across the continuum of patient care—from cardiology to primary care to emergency departments and beyond1 SAN FRANCISCO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital healthcare company focused on creating trusted solutions that detect, predict, and prevent disease, today announced it will use Epic's Aura platform to streamline access to iRhythm's Zio long-term continuous monitoring and ambulatory mobile cardiac telemetry services ("Zio services") through improved

    2/29/24 4:30:00 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    Pulmonx Announces Retirement of CEO Glen French and Appointment of Industry Veteran Steve Williamson as President and Chief Executive Officer

    REDWOOD CITY, Calif., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today announced that Glen French will retire as the Company's President and Chief Executive Officer, effective March 15, 2024, following over nine years of service to Pulmonx. Concurrently, the Company announced the appointment of Steve Williamson as President and Chief Executive Officer, and as a member of the Company's Board of Directors, also effective March 15, 2024. Mr. French will serve as a Senior Advisor to Mr. Williamson until May 1, 2024 to ensure a seamless transition and then remain a member of

    2/21/24 4:05:00 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    $IRTC
    $LUNG
    Financials

    Live finance-specific insights

    View All

    Pulmonx Reports Third Quarter 2025 Financial Results

    REDWOOD CITY, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (NASDAQ:LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the third quarter of 2025 ended September 30, 2025. Recent Highlights Achieved worldwide revenue of $21.5 million in the third quarter of 2025, a 5% increase over the same period last year and an increase of 4% on a constant currency basisDelivered $7.5 million in international revenue in the third quarter of 2025, representing 15% year-over-year growth and an increase of 9% on a constant currency basisDelivered $14.0 million in U.S. revenue in the third quarter of 20

    11/12/25 4:05:00 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    iRhythm Technologies Announces Third Quarter 2025 Financial Results

    SAN FRANCISCO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended September 30, 2025. Third Quarter 2025 Financial Highlights Revenue of $192.9 million, a 30.7% increase compared to third quarter 2024Gross margin of 71.1%, a 230-basis point increase compared to third quarter 2024Unrestricted cash, cash equivalents, and marketable securities of $565.2 million as of September 30, 2025Increased fiscal year 2025 guidance for revenue and adjusted EBITDA margin Recent Operational Highlights

    10/30/25 4:05:00 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    Pulmonx Announces Management Transition and Preliminary Third Quarter 2025 Revenue; Reschedules Third Quarter 2025 Earnings Call to November 12, 2025

    Glen French, member of the Board of Directors and former Pulmonx President and Chief Executive Officer, reappointed President and Chief Executive OfficerDerrick Sung, former Pulmonx Chief Financial Officer, appointed Chief Operating Officer and Chief Financial OfficerSteve Williamson and Mehul Joshi have resigned from their respective roles at the Company, effective immediatelyPreliminary, unaudited third quarter 2025 revenue expected to be approximately $21.5 millionThird quarter 2025 financial results rescheduled to be released after the close of trading on Wednesday, November 12, 2025; Management to host conference call to discuss the results and the transition at 1:30 p.m. PT / 4:30 p.m.

    10/27/25 4:05:00 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    $IRTC
    $LUNG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Pulmonx Corporation

    SC 13G/A - Pulmonx Corp (0001127537) (Subject)

    11/14/24 7:47:49 PM ET
    $LUNG
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by iRhythm Technologies Inc.

    SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)

    11/12/24 12:54:21 PM ET
    $IRTC
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Pulmonx Corporation

    SC 13G/A - Pulmonx Corp (0001127537) (Subject)

    11/12/24 10:34:16 AM ET
    $LUNG
    Medical/Dental Instruments
    Health Care